Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Viability of a MSQOL-54 general health-related quality of life score using bifactor model.
Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio ME, Pietrolongo E, Falautano M, Grobberio M, Niccolai C, Allegri B, Viterbo RG, Confalonieri P, Giovannetti AM, Cocco E, Grasso MG, Lugaresi A, Ferriani E, Nocentini U, Zaffaroni M, De Livera A, Jelinek G, Solari A, Rosato R. Giordano A, et al. Among authors: bertolotto a. Health Qual Life Outcomes. 2021 Sep 25;19(1):224. doi: 10.1186/s12955-021-01857-y. Health Qual Life Outcomes. 2021. PMID: 34563229 Free PMC article.
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group. Bertolotto A, et al. Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29. Neurol Sci. 2014. PMID: 24374787
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. Spadaro M, et al. Among authors: bertolotto a. J Neuroinflammation. 2015 Aug 12;12:146. doi: 10.1186/s12974-015-0365-x. J Neuroinflammation. 2015. PMID: 26259673 Free PMC article.
eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
Rosato R, Testa S, Bertolotto A, Scavelli F, Giovannetti AM, Confalonieri P, Patti F, Chisari CG, Lugaresi A, Pietrolongo E, Grasso MG, Rossi I, Toscano A, Loera B, Giordano A, Solari A. Rosato R, et al. Among authors: bertolotto a. Mult Scler. 2019 May;25(6):856-866. doi: 10.1177/1352458518774935. Epub 2018 May 15. Mult Scler. 2019. PMID: 29761738 Free article.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Italian consensus on treatment of spasticity in multiple sclerosis.
Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S; Italian Consensus Group on treatment of spasticity in multiple sclerosis. Comi G, et al. Eur J Neurol. 2020 Mar;27(3):445-453. doi: 10.1111/ene.14110. Epub 2019 Dec 3. Eur J Neurol. 2020. PMID: 31652369
372 results